loading
Precedente Chiudi:
$17.20
Aprire:
$17.45
Volume 24 ore:
256.04K
Relative Volume:
0.75
Capitalizzazione di mercato:
$603.00M
Reddito:
$4.12M
Utile/perdita netta:
$-56.68M
Rapporto P/E:
-3.2727
EPS:
-5.5429
Flusso di cassa netto:
$-51.44M
1 W Prestazione:
+5.04%
1M Prestazione:
-1.55%
6M Prestazione:
-20.79%
1 anno Prestazione:
-28.92%
Intervallo 1D:
Value
$17.34
$18.48
Intervallo di 1 settimana:
Value
$16.64
$18.48
Portata 52W:
Value
$13.37
$32.27

Dianthus Therapeutics Inc Stock (DNTH) Company Profile

Name
Nome
Dianthus Therapeutics Inc
Name
Telefono
929-999-4055
Name
Indirizzo
7 TIMES SQUARE, NEW YORK
Name
Dipendente
78
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
DNTH's Discussions on Twitter

Confronta DNTH con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
DNTH
Dianthus Therapeutics Inc
18.14 603.00M 4.12M -56.68M -51.44M -5.5429
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.27 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
522.27 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.00 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
568.06 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
266.80 28.51B 3.81B -644.79M -669.77M -6.24

Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-12-20 Iniziato TD Cowen Buy
2024-10-03 Iniziato Oppenheimer Outperform
2024-07-26 Iniziato Robert W. Baird Outperform
2024-06-27 Iniziato Cantor Fitzgerald Overweight
2024-05-16 Iniziato H.C. Wainwright Buy
2024-02-15 Iniziato Stifel Buy
2023-12-26 Iniziato Jefferies Buy
2023-11-22 Iniziato Wedbush Outperform
2023-10-30 Iniziato Guggenheim Buy
2023-09-28 Iniziato Raymond James Outperform
2022-08-25 Downgrade Goldman Buy → Neutral
2022-01-06 Aggiornamento Goldman Neutral → Buy
2021-08-20 Ripresa Goldman Neutral
2021-08-03 Downgrade JP Morgan Overweight → Neutral
2021-07-22 Reiterato B. Riley Securities Buy
2021-06-29 Iniziato Cantor Fitzgerald Overweight
2021-06-15 Iniziato BTIG Research Buy
2021-05-18 Iniziato B. Riley Securities Buy
2021-01-07 Iniziato Mizuho Buy
2020-06-08 Aggiornamento Goldman Neutral → Buy
2019-03-25 Downgrade Goldman Buy → Neutral
2019-03-15 Iniziato Raymond James Outperform
Mostra tutto

Dianthus Therapeutics Inc Borsa (DNTH) Ultime notizie

pulisher
Jun 18, 2025

Buy Rating for Dianthus Therapeutics: Promising Growth Potential of DNTH103 in Neuromuscular Disease Treatment - TipRanks

Jun 18, 2025
pulisher
Jun 14, 2025

Equities Analysts Issue Forecasts for DNTH FY2026 Earnings - MarketBeat

Jun 14, 2025
pulisher
Jun 13, 2025

Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 4.6%What's Next? - MarketBeat

Jun 13, 2025
pulisher
Jun 13, 2025

California State Teachers Retirement System Sells 1,352 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Two Sigma Investments LP Sells 588 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World

Jun 12, 2025
pulisher
Jun 08, 2025

Squarepoint Ops LLC Has $242,000 Stock Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Millennium Management LLC Has $1.97 Million Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat

Jun 07, 2025
pulisher
Jun 05, 2025

Bank of America Corp DE Sells 9,858 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World

Jun 05, 2025
pulisher
Jun 03, 2025

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Acquired by Millennium Management LLC - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

BNP Paribas Financial Markets Makes New Investment in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World

Jun 03, 2025
pulisher
Jun 01, 2025

Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 5.2%Time to Sell? - MarketBeat

Jun 01, 2025
pulisher
May 31, 2025

Analysts Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) PT at $53.00 - MarketBeat

May 31, 2025
pulisher
May 30, 2025

Deutsche Bank AG Increases Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World

May 30, 2025
pulisher
May 29, 2025

Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference - The Manila Times

May 29, 2025
pulisher
May 29, 2025

Autoimmune Disease Biotech Dianthus Therapeutics CEO Takes Stage at Major Jefferies Conference - Stock Titan

May 29, 2025
pulisher
May 26, 2025

Northern Trust Corp Acquires 42,923 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat

May 26, 2025
pulisher
May 26, 2025

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Purchased by Woodline Partners LP - MarketBeat

May 26, 2025
pulisher
May 26, 2025

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Recommendation of “Buy” from Brokerages - Defense World

May 26, 2025
pulisher
May 25, 2025

Point72 Asset Management L.P. Reduces Stock Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat

May 25, 2025
pulisher
May 24, 2025

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Acquired by Vestal Point Capital LP - MarketBeat

May 24, 2025
pulisher
May 23, 2025

Dianthus Therapeutics appoints new board member By Investing.com - Investing.com India

May 23, 2025
pulisher
May 23, 2025

Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors - citybiz

May 23, 2025
pulisher
May 22, 2025

Dianthus Therapeutics appoints new board member - Investing.com Australia

May 22, 2025
pulisher
May 22, 2025

Dianthus Therapeutics Announces Board Changes and Elections - TipRanks

May 22, 2025
pulisher
May 22, 2025

Former Novartis-Acquired CEO Joins Dianthus Board Ahead of Critical Phase 2 Data - Stock Titan

May 22, 2025
pulisher
May 21, 2025

Janus Henderson Group PLC Buys 136,314 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat

May 21, 2025
pulisher
May 20, 2025

Buy Rating Affirmed for Dianthus Therapeutics: Promising Clinical Potential of DNTH103 in CIDP Treatment - TipRanks

May 20, 2025
pulisher
May 19, 2025

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Position Raised by Octagon Capital Advisors LP - MarketBeat

May 19, 2025
pulisher
May 18, 2025

Robert W. Baird Has Lowered Expectations for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - MarketBeat

May 18, 2025
pulisher
May 18, 2025

FY2025 EPS Estimates for DNTH Lowered by Cantor Fitzgerald - Defense World

May 18, 2025
pulisher
May 18, 2025

Dianthus Therapeutics (NASDAQ:DNTH) Earns "Buy" Rating from HC Wainwright - MarketBeat

May 18, 2025
pulisher
May 17, 2025

Dianthus Therapeutics (NASDAQ:DNTH) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat

May 17, 2025
pulisher
May 17, 2025

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Bought by Price T Rowe Associates Inc. MD - Defense World

May 17, 2025
pulisher
May 16, 2025

Wedbush Research Analysts Raise Earnings Estimates for DNTH - Defense World

May 16, 2025
pulisher
May 16, 2025

HC Wainwright Issues Positive Forecast for DNTH Earnings - Defense World

May 16, 2025
pulisher
May 16, 2025

Tower Research Capital LLC TRC Sells 944 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World

May 16, 2025
pulisher
May 15, 2025

Robert W. Baird Issues Pessimistic Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - Defense World

May 15, 2025
pulisher
May 15, 2025

HC Wainwright Reaffirms Buy Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World

May 15, 2025

Dianthus Therapeutics Inc Azioni (DNTH) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.74
price up icon 0.29%
$36.14
price up icon 2.09%
$20.92
price up icon 2.60%
$105.90
price up icon 0.46%
$105.09
price up icon 2.02%
biotechnology ONC
$266.80
price up icon 3.61%
Capitalizzazione:     |  Volume (24 ore):